President Trump’s proposed budget for 2018, rife with deep cuts including a 20 percent funding reduction for the National Institutes of Health, has been greeted with a chorus of dismay from biopharma scientists and executives.

Talia Bronshtein/STAT Source: GPO: Budget of the United States Government

Consider the words used by industry veterans interviewed by STAT: “Pretty horrifying.” “A tragedy.” “Appalling.” “Incredibly short-sighted.” (One exception was the drug industry’s top lobbying group PhRMA, which put out a statement that … didn’t say much of anything.)

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy